Abstract: A medicated device comprises a substantially cylindrical, hollow body member having radially outwardly extending annular ridges at each end, a lengthwise slot, and inwardly extending flanges along the edges of the slot which have concave facing surfaces. A multi-layer, drug-bearing sheet material extends around the cylindrical member between and adjacent the annular ridges and has edge portions which extend into the slot. A cylindrical rod is disposed between the concave surfaces to clamp the sheet edge portions in the slot against the concave surfaces. End caps are mounted on each end of the cylindrical member, and each has a radially inwardly extending ridge which presses an adjacent edge of the sheet material against the cylindrical member.

Abstract: The present specification describes a medicated device adapted for a single and rate-controlled rectal or vaginal administration to a mammal of a systemically active pharmaceutical (SAP). The device accomplishes drug administration at an essentially time-independent rate of dosage. Further, the device advantageously results in the substantial exhaustion of the SAP from the device at the conclusion of the single, acute use. The device comprises three elements:(A) an inert resilient support means contoured for easy vaginal or rectal insertion;(B) a first flexible polymer film layer affixed to the support means and containing the SAP dispersed therethrough, this first polymer film not being rate limiting as to the release of drug from the device; and(C) a second polymer film, laminated onto the first polymer film and providing a release rate therefrom of prostaglandin, which is rate limiting both as to the release of prostaglandin from the device and absorption rate by the rectal or vaginal tissues.

Abstract: The present specification describes a medicated device adapted for a single, acute, and rate-controlled rectal or vaginal administration to a mammal of a lipophilic prostaglandin. The device accomplishes drug administration at an essentially time-independent rate of dosage. Further, the device advantageously results in the substantial exhaustion of the prostaglandin from the device at the conclusion of the single, acute use. The device comprises three elements:(A) an inert resilient support means contoured for easy vaginal or rectal insertion;(B) a first flexible polymer film layer affixed to the support means and containing the prostaglandin dispersed therethrough, this first polymer film not being rate limiting as to the release of drug from the device; and(C) a second polymer film, laminated onto the first polymer film and providing a release rate therefrom of prostaglandin, which is rate limiting both as to the release of prostaglandin from the device and absorption rate by the rectal or vaginal tissues.

Abstract: Novel vaginal devices containing prostaglandins and intended for use in accomplishing abortion in women in the first and second trimester of pregnancy and in inducing labor in pregnant women at or near term.